President & Chief Executive Officer, Board Member

Chief Financial Officer

Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target

Dianthus initiated with bullish view at Clear Street, here's why

Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

Director, Clinical Development Scientist

Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing novel monoclonal antibodies for severe autoimmune and inflammatory diseases. The Director, Clinical Development Scientist will lead clinical strategy for the APAC region, overseeing clinical study preparations, data interpretation, and ensuring compliance with GCPs and SOPs for the Myasthenia Gravis program.

Sign up with Google

Sign in with Google